Volume 9, Number 12—December 2003
Dispatch
Visceral Leishmaniasis Treatment, Italy
Luigi Gradoni*
, Marina Gramiccia*, and Aldo Scalone*
, Marina Gramiccia*, and Aldo Scalone*
Table
First-line drugs used for treatment of visceral leishmaniasis in 533 immunocompetent patients in Italy and drug treatment failures recordeda
| Y | MA (%) | L-AmB | ABCD | ABLC | dAmB | Any AmB drugs (%) |
|---|---|---|---|---|---|---|
| 1995 |
57 (55.9)
3 R |
45
1 R |
0 |
0 |
0 |
45 (44.1)
1 R |
| 1996 |
35 (50.0)
2 R |
35
1 R |
0 |
0 |
0 |
35 (50.0)
1 R |
| 1997 |
26 (39.4)
3 U, 1 R |
34
2 R |
5 |
0 |
1 |
40 (60.6)
2 R |
| 1998 |
14 (28.0)
1 R |
32
1 R |
4 |
0 |
0 |
36 (72.0)
1 R |
| 1999 |
13 (21.0)
1 U, 1 R |
45
2 R |
2 |
1 |
1 |
49 (79.0)
2 R |
| 2000 |
11 (9.8)
1 U, 3 R |
89
1 U, 1 R |
10
1 U |
1
1 R |
1 |
101 (90.2)
2 U, 2 R |
| 2001 |
2 (2.8) |
68
1 R |
0 |
1 |
0 |
69 (97.2)
1 R |
| Total | 158 (29.6) 5 U, 11 R | 348 1 U, 9 R | 21 1 U | 3 1 R | 3 | 375 (70.4) 2 U, 10 R |
aMA, meglumine antimoniate; L-AmB, liposomal amphotericin B; ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; dAmB, amphotericin B desoxycholate; U, unresponsiveness and/or acute toxicity; R, relapse.
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.